COST EFFECTIVENESS ANALYSIS OF LAPATINIB/CAPECITABINE (LC) VERSUS TRASTUZUMAB/CAPECITABINE (TC) IN PATIENTS WITH METASTATIC BREAST CANCER ERBB2+AFTER PROGRESSION TO THE FIRST SCHEME OF TRASTUZUMAB

被引：0
|
作者：
Anaya, P. [1 ]
Aldaco, F. [2 ]
机构：
[1] GlaxoSmithKline Inc, Mexico City, DF, Mexico
[2] GSK Mexico & Natl Med Ctr 20 Noviembre, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.914
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
  • [2] COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Passos, R. B. F.
    Teich, N.
    Canella, M.
    VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
  • [3] Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer
    Bian, Li
    Wang, Tao
    Zhang, Shaohua
    Jiang, Zefei
    TUMOR BIOLOGY, 2013, 34 (05) : 3153 - 3158
  • [4] Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+advanced or metastatic breast cancer (MBC) patients (PTS) pretreated with chemotherapy and trastuzumab
    Cameron, D. A.
    Geyer, C. E.
    Chan, D. S.
    Pienkowski, T.
    Romieu, C. G.
    Jagiello-Gruszfeld, A.
    Crown, J.
    Oliva, C.
    Newstat, B.
    Bailey-Tippets, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 69 - 70
  • [5] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION
    Vondeling, G.
    Palaka, E.
    Livings, C.
    Naik, J.
    Sullivan, W.
    VALUE IN HEALTH, 2020, 23 : S433 - S434
  • [6] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [7] COST-EFFECTIVENESS ANALYSIS OF ADO-TRASTUZUMAB EMTANSINE COMPARED TO LAPATINIB-CAPECITABINE COMBINATION IN HER2-POSITIVE METASTATIC BREAST CANCER
    Gor, D.
    Lee, W.
    Kim, K.
    Mohan, A.
    Peng, K.
    Sarangpur, S.
    Shinde, S.
    Touchette, D.
    VALUE IN HEALTH, 2015, 18 (03) : A205 - A205
  • [8] Lapatinib plus capecitabine in ErbB2-positive metastatic breast cancer patients
    Poinsignon, V.
    PHARMACY WORLD & SCIENCE, 2008, 30 (06): : 1023 - 1024
  • [9] Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
    Yang, Fan
    Huang, Xiang
    Sun, Chunxiao
    Li, Jianbin
    Wang, Biyun
    Yan, Min
    Jin, Feng
    Wang, Haibo
    Zhang, Jin
    Fu, Peifen
    Zeng, Tianyu
    Wang, Jian
    Li, Wei
    Li, Yongfei
    Yang, Mengzhu
    Li, Jun
    Wu, Hao
    Fu, Ziyi
    Yin, Yongmei
    Jiang, Zefei
    BMC CANCER, 2020, 20 (01)
  • [10] Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
    Fan Yang
    Xiang Huang
    Chunxiao Sun
    Jianbin Li
    Biyun Wang
    Min Yan
    Feng Jin
    Haibo Wang
    Jin Zhang
    Peifen Fu
    Tianyu Zeng
    Jian Wang
    Wei Li
    Yongfei Li
    Mengzhu Yang
    Jun Li
    Hao Wu
    Ziyi Fu
    Yongmei Yin
    Zefei Jiang
    BMC Cancer, 20
12345